EAM Global Investors’s Madrigal Pharmaceuticals MDGL Stock Holding History

EAM Global Investors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,510	Closed	-$2.79M	–	105
2023 Q1	$2.79M	Buy	11,510 +5,874	+104%	+$1.6M	0.78%	79
2022 Q4	$1.64M	Buy	+5,636	New	+$551K	0.42%	123
2018 Q4	–	Sell	-3,340	Closed	-$715K	–	151
2018 Q3	$715K	Sell	3,340 -1,706	-34%	-$428K	0.29%	146
2018 Q2	$1.41M	Sell	5,046 -3,054	-38%	-$536K	0.69%	57
2018 Q1	$946K	Buy	+8,100	New	+$1,000K	0.49%	112

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

EAM Global Investors's MDGL Position: Q2 2023 in Review

EAM Global Investors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 11,510 shares — an estimated $2.79M sold.

EAM Global Investors first reported a position in MDGL in Q1 2018 and held it in 5 quarters. The position peaked at $2.79M in Q1 2023. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

EAM Global Investors reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
EAM Global Investors sold 11,510 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $2.79M.
EAM Global Investors first reported a position in Madrigal Pharmaceuticals in Q1 2018 and held it in 5 quarters.
EAM Global Investors's Madrigal Pharmaceuticals position peaked at $2.79M in Q1 2023.
208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on EAM Global Investors's 13F filing for Q2 2023, filed 11 Aug 2023.